skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: BACON - Mir@bel - GLOBAL_LIBRESACCES remover tipo de recurso: Anais de Congresso remover Publisher or Other Site remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED ANALYSIS OF POLLUX
EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED ANALYSIS OF POLLUX
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED ANALYSIS OF POLLUX

Dimopoulos, MA ; Moreau, P ; Nahi, H ; Plesner, T ; Goldschmidt, H ; Suzuki, K ; Orlowski, RZ ; Rabin, N ; Leiba, M ; Oriol, A ; Chari, A ; San-Miguel, J ; Richardson, PG ; Usmani, SZ ; O'Rourke, L ; Wu, K ; Casneuf, T ; Chiu, C ; Qin, X ; Bahlis, NJ

HAEMATOLOGICA, 2017, Vol.102, p.108 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY STUDY IN ADVANCED MULTIPLE MYELOMA - AN OPEN-LABEL, DOSE ESCALATION FOLLOWED BY OPEN-LABEL EXTENSION IN A SINGLE-ARM PHASE I/II STUDY
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY STUDY IN ADVANCED MULTIPLE MYELOMA - AN OPEN-LABEL, DOSE ESCALATION FOLLOWED BY OPEN-LABEL EXTENSION IN A SINGLE-ARM PHASE I/II STUDY
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY STUDY IN ADVANCED MULTIPLE MYELOMA - AN OPEN-LABEL, DOSE ESCALATION FOLLOWED BY OPEN-LABEL EXTENSION IN A SINGLE-ARM PHASE I/II STUDY

Lokhorst, H ; Plesner, T ; Gimsing, P ; Nahi, H ; Lisby, S ; Richardson, P

HAEMATOLOGICA, 2013, Vol.98, p.241 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX
This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX

Dimopoulos, MA ; Oriol, A ; Nahi, H ; Miguel, JS ; Bahlis, NJ ; Rabin, N ; Orlowski, R ; Komarnicki, M ; Suzuki, K ; Plesner, T ; Samoilova, OS ; Yoon, SS ; Yehuda, DB ; Richardson, PG ; Goldschmidt, H ; Reece, D ; Khokhar, N ; O'Rourke, L ; Chiu, C ; Qin, X ; Guckert, M ; Ahmadi, T ; Moreau, P

HAEMATOLOGICA, 2016, Vol.101, p.342 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
ANTI-MYELOMA ACTIVITY OF A NOVEL ALKYLATING AGENT MELPHALAN- FLUFENAMIDE
ANTI-MYELOMA ACTIVITY OF A NOVEL ALKYLATING AGENT MELPHALAN- FLUFENAMIDE
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

ANTI-MYELOMA ACTIVITY OF A NOVEL ALKYLATING AGENT MELPHALAN- FLUFENAMIDE

Chauhan, D ; Ray, A ; Viktorsson, K ; Spira, J ; Paba-Prada, C ; Richardson, P ; Lewensohn, R ; Anderson, K

HAEMATOLOGICA, 2013, Vol.98, p.88 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - PRELIMINARY EFFICACY AND PHARMACOKINETICS DATA FROM A DOSE-ESCALATION PHASE I/II STUDY
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - PRELIMINARY EFFICACY AND PHARMACOKINETICS DATA FROM A DOSE-ESCALATION PHASE I/II STUDY
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - PRELIMINARY EFFICACY AND PHARMACOKINETICS DATA FROM A DOSE-ESCALATION PHASE I/II STUDY

Lokhorst, H ; Gimsing, P ; Nahi, H ; Richardson, P ; Plesner, T ; Lisby, S

HAEMATOLOGICA, 2012, Vol.97, p.473 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)

Lokhorst, H ; Laubach, J ; Nahi, H ; Plesner, T ; Gimsing, P ; Hansson, M ; Minnema, M ; Lassen, U ; Krejcik, J ; Ahmadi, T ; Khan, I ; Uhlar, C ; Lisby, S ; Basse, L ; Brun, N ; Richardson, P

HAEMATOLOGICA, 2014, Vol.99, p.106 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. Discussion
Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. Discussion
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. Discussion

SNDARESAN, S ; SEMENKOVICH, J ; OCHOA, L ; RICHARDSON, G ; TRULOCK, E. P ; COOPER, J. D ; PATTERSON, G. A ; LOCICERO, J ; EGAN, T. M

Journal of thoracic and cardiovascular surgery, 1995, Vol.109 (6), p.1075-1080 [Periódico revisado por pares]

Philadelphia, PA: Elsevier

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.